MED64 Application Specialists
A complete, easy-to-use Multi-Electrode Array based solution for
advanced in vitro multi-site extracellular electrophysiology.
home  |   products  |   applications  |   resources  |   support  |   contact
Publications
Search Our Site:
  Journals and Abstracts
  FAQs
  Technology Overview
  Utilities and Methods
  Software Resources

MED64 Journals

Nonphotic entrainment of the circadian body temperature rhythm by the selective ORL1 receptor agonist W-212393 in rats.

Teshima K, Minoguchi M, Tounai S, Ashimori A, Eguchi J, Allen CN, Shibata S
Br J Pharmacol 2005 Sep;146(1):33-40.

1Research Laboratory I (CNS), Pharmaceutical Research Unit, R&D Division, Mitsubishi Pharma Corporation, 3-7-25, Koyata, Iruma, Saitama 358-0026, Japan.

We synthesized a small-molecule opioid receptor-like 1 (ORL1) receptor agonist, 2-{3-[1-((1R)-acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimida zol-1-yl}-N-methylacetamide (W-212393), and investigated its effect on the circadian body temperature rhythm of rats.W-212393 has high affinity for ORL1 receptors in the rat cerebral cortex and human ORL1 receptors expressed in HEK293 cells with K(i) values of 0.76 and 0.50 nM, respectively.W-212393 concentration-dependently stimulated GTPgamma(35)S binding and its efficacy was similar to nociceptin/orphanin FQ (N/OFQ), suggesting that W-212393 is a full agonist at ORL1 receptors.W-212393 dose-dependently occupied ORL1 receptors following intraventricular or intraperitoneal administration, suggesting that W-212393 is a brain-penetrating compound.W-212393 (100 nM) and N/OFQ (100 nM) significantly suppressed the activity of spontaneously firing rat suprachiasmatic nucleus neurons. These suppressive effects were blocked by an ORL1 receptor antagonist, J-113397 (1 muM).W-212393 (3 mg kg(-1), i.p.) induced a significant phase advance at circadian time 6 (CT6) and CT9, but not at other CTs. The magnitude of the W-212393 (0.3-3 mg kg(-1), i.p.)-induced phase advance was dose-dependent and greater than those produced by 8-hydroxy-2-(di-n-propylamino)tetralin (0.3-3 mg kg(-1), i.p.) or melatonin (0.3-3 mg kg(-1), i.p.). The W-212393 (3 mg kg(-1), i.p.)-induced phase advance was antagonized by J-113397 (10 mg kg(-1), i.p.).W-212393 (3 mg kg(-1), i.p.) significantly accelerated the re-entrainment of the body temperature rhythm to a 6 h advanced light-dark cycle.These results indicate that activation of ORL1 receptors contributes to the circadian entrainment and W-212393 may represent an interesting agent for the study of circadian rhythms.British Journal of Pharmacology (2005) 146, 33-40. doi:10.1038/sj.bjp.0706311; published online 27 June 2005

 

 

Home | Products | Applications | Resources | Support | Site Map | Contact
Copyright © 1995-2010 Alpha Med Sciences.
Web Hosting Provided by EPhost